peptide research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== Colored particles === In principle, any colored particle can be used, but latex (blue color) or nanometer-sized particles of gold (red color) are most commonly used. The gold particles are red in color due to localized surface plasmon resonance. Fluorescent or magnetic labelled particles can also be used, but these require the use of an electronic reader to assess the test result.
=== Interactions === IRAP has been reported to interact through its cytoplasmic domain with various proteins involved in vesicular trafficking, organelle tethering, and cytoskeleton remodeling. These proteins include tankyrase-1, tankyrase-2, and p115, which regulate Golgi vesicle trafficking; vimentin, an intermediate cytoskeleton filament; and the actin remodeling protein FHOS. Furthermore, IRAP was found to associate with AS160/Tbc1d4, a Rab GTPase activating protein (GAP) specific for Rab8, 10, and 14. This suggests that IRAP plays a role in recruiting AS160 to endocytic membranes. Apart from its association with intracellular trafficking proteins, IRAP has also been also observed to interact with proteins present in Glut4 storage vesicles (GSVs), such as sortilin, LRP1 and Glut4 in adipocytes. Under inflammatory conditions its role in GSV trafficking in adipocytes is regulated by the TNFa protein via glycosylation. Recently, its interaction with the z chain of the TCR (T-cell receptor) and the Lck kinase in T lymphocytes was discovered. In dendritic cells, IRAP-dependent vesicle trafficking and translocation to the phagocytic cup is regulated by immune receptors, such as TLR4 and FcgRs. Finally, IRAP has been proposed to interact with major histocompatibility complexes class-I (MHC-I) in specialized endosomes in DCs. There it exhibits roles in antigen cross-presentation.
Following a Round 22 61-point demolition at the hands of lower-placed Hawthorn, Thompson's job was under immense pressure. After a very public review of the club, it was decided that Thompson should keep his job as senior coach. After a shaky start to the 2007 season that led many supporters to believe that nothing had changed from the 2006 season, Thompson led Geelong to a massive 15 match winning streak (the biggest in a single season in club history) and a 106-point win against the Kangaroos in the Qualifying Final which is the 5th biggest finals winning margin in AFL/VFL history. The 2007 season then culminated in one of the biggest, if not the best highlight of Thompson's career, in both a coaching and footballer's role. Thompson coached Geelong to win the AFL premiership in the 2007 AFL Grand Final by more than 100 points, which was the highest winning margin in Grand Final history, against Port Adelaide Football Club at the MCG on 29 September. It was the club's first premiership since 1963, the year of Thompson's birth. After the Essendon Football Club decided not to give Thompson's former mentor, Kevin Sheedy, a renewal of contract, there was speculation that Mark Thompson would take up the senior coaching role at Essendon for the 2008 season. However, with trade week quickly approaching, the club instead appointed Matthew Knights to the position. After Geelong's record-breaking win in the grand final, Geelong under Thompson were red hot favourite to repeat their 2007 success in the 2008 season and their form during the year did nothing to change that.
=== Indirect mechanism === There are many types of drugs that unintentionally lower sexual desire through indirect mechanisms. It is one of their side-effects as the outcome of libido suppression is not intended. SSRIs reduce the re-uptake of serotonin back to the neurons, leading to an increase in serotonin level in the body. Due to the fact that serotonin can interfere with other neurotransmitters and hormones, for instance, sex hormones, SSRIs can therefore lower sexual desire. Apart from SSRIs, other types of drugs that could lower sexual desire are not intended to suppress libido originally. Thus, sexually active people are suggested to avoid the usage of the following drugs:
Sources: en.wikipedia.org
==== Parenteral ==== Intradermally-administered (ID) Subcutaneously-administered (SC) Intramuscularly-administered (IM) Intraosseous administration (IO) Intraperitoneally-administered (IP) intravenously-administered (IV) Intracavernously-administered (ICI) These are usually solutions and suspensions.
=== Nitrogen reserve === Cyanophycin is a polymer consisting of a backbone of aspartic acid units with arginine side chains. It is synthesized by cyanobacteria and other bacteria either directly from arginine and aspartic acid or from the corresponding dipeptide, β-aspartylarginine, and serves as a nitrogen storage compound. In plants, particularly trees, arginine also plays a role in nitrogen storage. Under conditions of increased nitrogen availability, arginine—having the highest nitrogen content among amino acids—is preferentially synthesized and stored either as a free amino acid or within proteins. Trees also possess transport proteins for the uptake of arginine from the soil, and in conifers it represents a preferred nitrogen source. Various studies have shown that the xylem of trees contains high concentrations of free arginine compared to other amino acids, for example in citrus plants. Arginine is mobilized from arginine-containing storage proteins when needed. It also serves as a nitrogen source during germination, as demonstrated in studies on maritime pine.
==== Variation between animal species ==== Studies on the cell membranes of mammals and reptiles discovered that mammalian cell membranes are composed of a higher proportion of polyunsaturated fatty acids (DHA, omega−3 fatty acid) than reptiles. Studies on bird fatty acid composition have noted similar proportions to mammals but with 1/3rd less omega−3 fatty acids as compared to omega−6 for a given body size. This fatty acid composition results in a more fluid cell membrane but also one that is permeable to various ions (H+ & Na+), resulting in cell membranes that are more costly to maintain. This maintenance cost has been argued to be one of the key causes for the high metabolic rates and concomitant warm-bloodedness of mammals and birds. However polyunsaturation of cell membranes may also occur in response to chronic cold temperatures as well. In fish increasingly cold environments lead to increasingly high cell membrane content of both monounsaturated and polyunsaturated fatty acids, to maintain greater membrane fluidity (and functionality) at the lower temperatures.
Sources: en.wikipedia.org
Take potato slices, stew them with butter, chopped marjoram and parsley; simultaneously whisk four or five egg yolks with a little wine, pour them into the boiling potatoes, remove from heat and serve. (French: Autrement. Prennez la tartoufle par tranches, & mettez eſteuuer auec beurre, mariolaine haſchee, du persin : puis prennez quatre ou cinq iaulnes d'œuf battus auec vn peu de vin, & iettez le deſſus tout en bouillãt, & tirez arriere du feu, & seruez ainsi.)
=== Recreational drug use === Subcutaneous injection may also be used by people to (self-) administer recreational drugs. This can be referred to as skin popping. In some cases, the administration of illicit drugs in this way is associated with unsafe practices leading to infections and other adverse effects. In rare cases, this results in serious side effects such as AA amyloidosis. Recreational drugs reported to be administered subcutaneously have included cocaine, mephedrone, and amphetamine derivatives such as PMMA.
Azoospermia factor (AZF) is one of several proteins or their genes, which are coded from the AZF region on the human male Y chromosome. Deletions in this region are associated with inability to produce sperm. Subregions within the AZF region are AZFa (sometimes AZF1), AZFb and AZFc (together referred to as AZF2). AZF microdeletions are one of the major causes of male infertility for azoospermia (complete absence of sperm in the ejaculate) and severe oligozoospermia (less than 5 million spermatozoa in the ejaculate) males. AZF is the term used by the HUGO Gene Nomenclature Committee. Of the 15% of couples who are affected by infertility, 50% of those cases are due to the male partner. 15-30% of male factor infertility cases can be correlated with genetic abnormalities. One of the most commonly identified genetic abnormalities in male factor infertility are microdeletions on the long arm of the Y chromosome (Yq), specifically at a region known as the azoospermic factor (AZF) region. In certain circumstances, men with AZF mutations can turn to assisted reproductive technologies (ART), such as intracytoplasmic sperm injection (ICSI), to help them overcome their suboptimal sperm quality. However, it may be more important for clinicians to screen for Yq microdeletions, due to a growing body of evidence that AZF microdeletions have the capability to be vertically transmitted to male offspring. Minor et al. demonstrated that an AZFc mutation was vertically transmitted over three generations via fathers receiving reproductive assistance through ICSI.
A rare, but serious, side effect is propofol infusion syndrome. This potentially lethal metabolic derangement has been reported in critically ill patients after a prolonged infusion of high-dose propofol, sometimes in combination with catecholamines and/or corticosteroids.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.